Business Wire

NC-PERCONA

23.5.2023 15:01:36 CEST | Business Wire | Press release

Share
The Percona 2023 State of Open Source Database Survey Reveals Reluctance Among Businesses to Alter Database Strategies in the Face of Economic Uncertainty

Percona, a leader in enterprise-grade open source database software, support, and services, today announced the initial findings of its State of Open Source Database Survey report for 2023 during its annual Percona Live conference. According to the survey of nearly 300 database professionals working in companies ranging in size from small-to-medium-sized business to large enterprise, the database market is currently in a period of stasis around database deployments and changes, most likely due to economic uncertainty and post-COVID-19 recovery. The research indicates that most organizations are not planning to make significant alterations to their database strategies over the course of the next three years.

Alongside this broader revelation, the study sheds light on a number of database operations concerns for organizations, including challenges around developer agility, and significant factors driving the choice between deploying open source or proprietary databases.

Findings in the 2023 State of Open Source Database Survey include:

  • More respondents indicate their organizations are doing well with a host of database operations metrics than they are with meeting developer needs:
    • More than 70 percent of respondents say they are doing somewhat or extremely well with database reliability, performance, security, privacy, scalability and backup reliability and integrity.
    • Conversely, meeting the needs of developers placed last on the list of 14 operational metrics collected, with only 55 percent of respondents saying they are doing well in developer agility.
  • Comparing large enterprises and small-to-medium businesses, the research shows that bigger companies tend to have more tools and automation deployed to help their teams:
    • Large enterprises are much more likely to use database monitoring and management solutions, with 93 percent of organizations having such tools in place. Conversely, only 57 percent of small businesses have database monitoring and management solutions deployed.
    • Small companies are much more likely to use on-premises and cloud services to host their databases (49 percent) compared to 26 percent of large enterprises. Large enterprises are also much more likely to use DBaaS offerings (32 percent of deployments).

“Our report indicates that database deployment strategies are expected to remain static for the next few years, with levels of usage remaining consistent across all categories of relational and non-relational databases,” said Joe Brockmeier, Head of Community at Percona. “We’re seeing caution around making significant changes to deployments following the large-scale digital transformation undertaken during the pandemic and the uncertain economic climate the world is facing in 2023. Teams want to improve how they manage, monitor and run those deployments rather than implementing more changes.”

Further findings include:

  • When asked about what drove their choice to use open source databases, respondents most often cited cost reductions (83 percent rated as somewhat or extremely significant) and developer choice (81 percent), followed by faster deployment (75 percent) and then security and more control (73 percent each).
  • For respondents that implemented proprietary databases, the findings are very different – the biggest factors are greater stability (68 percent), more security (63 percent) and regulatory compliance (61).
  • Developer choice was not in the top ten reasons to deploy proprietary databases, pointing to a much larger preference for open source solutions for the developer community.
  • The majority of respondents say their organizations rely on both relational and non-relational databases – 99 percent of respondents run at least one relational database, and 86 percent run at least one non-relational database.
    • MySQL is the most popular relational database, followed by PostgreSQL and Oracle Server at 57, 48 and 47 percent respectively.
    • MongoDB is the most commonly deployed non-relational database, followed by Couchbase and Redis.

“Developers prefer open source software where they have choice and autonomy over how they can architect and build their applications. The flexibility and performance benefits aside, open source also helps companies save on costs compared to running proprietary databases, which can’t be ignored in today’s economy. However, companies can still improve how they run and manage those installations, and that is where Percona can really help,” said Ann Schlemmer, CEO at Percona.

Speakers at this year’s Percona Live will discuss these and other findings from the 2023 survey. Percona Live is sponsored by a range of companies in the data and database markets, including Microsoft, AWS, Oracle, PlanetScale, FerretDB, Datavail, OtterTune, benchAnt, Victoria Metrics, Civo, and DBeaver.

If you would like to be notified when the full report from this survey is made available, please send an email with the request to: databasesurvey@percona.com

About Percona

Percona is widely recognized as a world-class open source database software, support, and services company. The organization is dedicated to helping businesses make databases and applications run better through a unique combination of expertise and open source software. Percona works with numerous global brands across many industries, creating a unified experience to monitor, manage, secure, and optimize database environments on any infrastructure.

Percona equips organizations with the freedom to choose, the freedom to create, and the freedom to make a difference - helping them scale and innovate with speed as they grow. For more information, visit www.percona.com.

Databases run better with Percona.

Percona® is a registered trademark of Percona LLC. All other registered and unregistered trademarks in this document are the sole property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005396/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye